Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.79 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | CTSD | P07339 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17119139 | 1.00 | BACE1 (1.00) | BACE1CYP2D6BACE2CYP2C9KCNH2 | |
| SCHEMBL17119169 | 0.93 | BACE1 (1.00) | BACE1CYP2D6BACE2CTSD | |
| SCHEMBL17119187 | 0.93 | BACE1 (0.87) | BACE1CYP2D6BACE2CYP2C9KCNH2 | |
| SCHEMBL18636900 | 0.90 | BACE1 (0.82) | BACE1CYP2D6BACE2CYP2C9KCNH2 | |
| SCHEMBL17119276 | 0.90 | BACE1 (0.82) | BACE1CYP2D6BACE2CYP2C9KCNH2 | |
| SCHEMBL17169040 | 0.89 | BACE1 (0.90) | BACE1CYP2D6BACE2CYP2C9KCNH2 | |
| SCHEMBL17119166 | 0.88 | BACE1 (0.87) | BACE1CYP2D6BACE2 | |
| SCHEMBL17119327 | 0.88 | BACE1 (1.00) | BACE1CYP2D6BACE2 | |
| SCHEMBL18636679 | 0.88 | BACE1 (1.00) | BACE1CYP2D6BACE2CYP2C9KCNH2 | |
| SCHEMBL17169038 | 0.88 | BACE1 (1.00) | BACE1CYP2D6BACE2CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758513-B2 | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20170008881-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2017-01-12 | — | — | US | disclosed |
| US-9540359-B2 | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20150266865-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266865-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885CYP2D6 1534/4885BACE2 3/4885 |
| US-20170008881-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885CYP2D6 1534/4885BACE2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.